Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma By Ogkologos - September 21, 2026 68 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final 5-year analysis of overall survival in the IMCgp100-202 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally... August 4, 2025 Post-Mastectomy Boutique Set to Close After 12 Years, As Owner Has... March 12, 2019 Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease... June 19, 2019 Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer March 31, 2026 Load more HOT NEWS Why haven’t we cured cancer? Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to... 20 years on: how we’ve decreased cancer death rates Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with...
